SCHEMBL490873

SCHEMBL490873

O=C(O)CCc1cc(O)c(O)c(O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.52
PCNA P12004 2/20 0.51
SELP P16109 6/20 0.50
SELL P14151 5/20 0.50
SELE P16581 5/20 0.50
MAPK1 P28482 2/20 0.49
POLB P06746 1/20 0.49
THRA P10827 1/20 0.49
THRB P10828 1/20 0.49
HIF1A Q16665 1/20 0.49
FFAR1 O14842 3/20 0.48
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
KDM4E B2RXH2 1/20 0.44
CA12 O43570 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
CA3 P07451 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19857034 0.87 HDAC3 (0.55) SELPSELLSELEMAPK1FFAR1
SCHEMBL31672996 0.85 MAPT (0.55) SELPSELLSELEMAPK1LMNA
SCHEMBL25363485 0.83 ALOX5 (0.60) POLBFFAR1CA1CA2CA12
SCHEMBL5670212 0.83 KEAP1 (0.64) KEAP1PCNAMAPK1THRATHRB
SCHEMBL28122739 0.83 KEAP1 (0.48) KEAP1PCNAMAPK1POLBTHRA
SCHEMBL3197224 0.81 SELP (0.43) PCNASELPSELLSELECA1
SCHEMBL9787441 0.79 SELP (0.45) PCNASELPSELLSELEMAPK1
SCHEMBL490382 0.79 KEAP1 (0.54) KEAP1PCNATHRATHRBFFAR1
Dihydrocaffeic Acid SCHEMBL245530 0.78 IAPP (0.65) KEAP1MAPK1POLBHIF1AFFAR1
Dihydrocaffeic Acid SCHEMBL7058919 0.78 IAPP (0.65) KEAP1MAPK1POLBHIF1AFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12044969-B2 Resist underlayer film-forming composition NISSAN CHEMICAL CORPORATION (JP) 2024-07-23 US disclosed
US-12044969-B2 Resist underlayer film-forming composition NISSAN CHEMICAL CORPORATION (JP) 2024-07-23 US disclosed
US-11976219-B2 Photo-cleavable primer compositions and methods of use ORMCO CORPORATION (US) 2024-05-07 US disclosed
EP-4346810-A1 COMPOSITIONS FOR REGULATING HOMEOSTASIS OF CORTISOL AND IMPROVING SLEEP QUALITY AND METHODS OF USE AND PRODUCTION THEREOF Unigen, Inc. (US) 2024-04-10 EP disclosed
CN-117794534-A Compositions for modulating cortisol homeostasis and improving sleep quality and methods of use and preparation thereof 尤尼根公司 2024-03-29 CN disclosed
US-11739223-B2 Surface primer compositions and methods of use ENVISTA (US) 2023-08-29 US disclosed
US-11739223-B2 Surface primer compositions and methods of use ENVISTA (US) 2023-08-29 US disclosed
US-11739223-B2 Surface primer compositions and methods of use ENVISTA (US) 2023-08-29 US disclosed
US-20230112086-A1 PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE ORMCO CORPORATION 2023-04-13 US disclosed
US-20230112086-A1 PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE ORMCO CORPORATION 2023-04-13 US disclosed
CN-103342729-B Substituted ramification of pentacycle triterpene of coffee acyl and application thereof 中国科学院上海药物研究所 2016-09-14 CN disclosed
CN-103342729-A Caffeoyl substituted pentacyclic triterpenoid derivatives and purpose thereof SHANGHAI INST MATERIA MEDICA 2013-10-09 CN disclosed
US-8268293-B2 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2012-09-18 US disclosed
US-8106233-B2 Applying di-2-ethylhexyl 4-hydroxy-3,5-dimethoxy-benzylmalonate; protective action against UV rays, oxidative stress on body cells, counters skin ageing MERCK PATENT GMBH (DE) 2012-01-31 US disclosed
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives MERCK PATENT GMBH (DE) 2008-07-17 US disclosed
US-20080152603-A1 Antioxidants SUSONITY Commercial GmbH (DE) 2008-06-26 US disclosed
EP-1871735-A1 ANTIOXIDANTS Merck Patent GmbH (DE) 2008-01-02 EP disclosed
EP-1871339-A1 UV PROTECTION Merck Patent GmbH (DE) 2008-01-02 EP disclosed
WO-2006111234-A1 UV PROTECTION MERCK PATENT GMBH (DE) 2006-10-26 WO disclosed
WO-2006111233-A1 ANTIOXIDANTS MERCK PATENT GMBH (DE) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080152603-A1 Antioxidants GPX4, GPX1, CAT KEAP1 78/4885PCNA 1028/4885SELP 1648/4885
US-20080171004-A1 Using compounds which do not themselves exhibit significant UV absorption in the UV-A or UV-B region, but are reactive under use conditions, such as 4-hydroxyphenylpropionic acid, or 2-ethylhexyl 4-hydroxy-3,5-dimethoxycinnamate, or polysiloxanes which contain benzylidenemalonic acid derivatives HPD, HAAO, UGT1A6 KEAP1 1030/4885PCNA 44/4885SELP 2008/4885
US-20230112086-A1 PHOTO-CLEAVABLE PRIMER COMPOSITIONS AND METHODS OF USE SP1, GPER1, ESR1 KEAP1 1178/4885PCNA 297/4885SELP 1228/4885
US-11739223-B2 Surface primer compositions and methods of use SP1, GPER1, GRIN1 KEAP1 2655/4885PCNA 1096/4885SELP 157/4885
US-11976219-B2 Photo-cleavable primer compositions and methods of use SP1, GPER1, ESR1 KEAP1 1178/4885PCNA 297/4885SELP 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.